Type 2 Diabetes Trial, Recruiting NCT06007404 Sponsor: University of Michigan Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06007404
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 14 and 18 years old
  • People who are at Tanner stage 4 or 5, meaning they are in the later or final stages of puberty (confirm with trial site)
  • People whose body weight falls into the normal range, overweight range, or obese range based on BMI percentile charts for their age, or who have pre-diabetes based on a blood sugar measurement called HbA1c
  • People who have been diagnosed with Type 2 Diabetes (for a specific group within the trial)

Who may not be able to join:

  • People who are currently pregnant
  • People who are taking certain medications known to affect blood sugar levels, such as immunosuppressive drugs, cancer treatments, or high-dose steroids — unless those medications are being used specifically to manage Type 2 Diabetes
  • People who have previously been diagnosed with an autoimmune disease, cancer, or a cognitive or perceptual disability that would make it difficult to follow instructions from study staff
  • People who have an allergy or intolerance to milk, soy, or palm oil

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kanakadurga Singer, MA, MD, University of Michigan

Phone: (734) 615-4938

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 September 2023
Est. completion
1 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Glucose (OGTT); Insulin (OGTT); Glucose (MMTT); Insulin (MMTT); Monocyte /macrophage populations by flow cytometry

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov